Clinical Trial Search

Primary: Time to First Protocol-Defined Relapse (TFR) During the Double-Blind (DB) Period — 128.3; NA weeks — p=0.0184

Primary: The Proportion of Participants Who Achieve an ASAS 20 Response (Assessment of SpondyloArthritis International Society Criteria) — 178; 56 Participants — p=<.0001

Primary: Absolute Change From Baseline in Inflammatory Lesion Count at Week 40 — 23.0; 22.5 Lesions

Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12: Intent-to-Treat (ITT) Analysis — -4.1 percent change

Primary: Percentage of Participants With Overall Success — 301; 325 Participants

Primary: Percentage of Participants With Local Reactions Within 10 Days After Vaccination in All Cohorts — 7.3; 6.2; 8.2; 5.4 percentage of participants

Primary: Bone Loss Reduction: Mean Percent Changes in BMD for Each Treatment Arm at the 6 Months — -2.4; -3.5; -7.6; -11 Percent of change

Primary: FEV1 AUC0-4 — 0.292; 0.288; 0.177; 0.189 Liters

Primary: Change in PANSS Total Score From Baseline at Week 6 — 99.5; 101.6; 101.5; -10.8 units on a scale — p=0.007

Primary: Percentage of Participants With Freedom From Pain at 2 Hours Post-dose — 19.2; 14.2 percentage of participants — p=0.0298

Primary: Efficacy of a Fixed Dose of Bremelanotide as Measured by FSFI (Question Q1 and Q2), 28-day Recall. — 0.54; 0.24; 1.30; 0.77 score on a scale

Primary: Percentage of Participants With Freedom From Pain at 2 Hours Post-dose — 19.6; 12.0 Percentage of participants — p=0.0006

Primary: Peak Percent Dose Recovery (PDR) Value — 10.2; 1.9 percentage per hour

Primary: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) — 4.8…

Primary: Resolution of Anterior Chamber Cells — 48; 39; 19 Participants — p=.0024